Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) announces the commencement of dosing in a Phase 1 clinical trial assessing the safety and pharmacokinetics of oral formulations of zavegepant, a third-generation calcitonin gene-related peptide (CGRP) receptor antagonist in development for the potential treatment of migraine.
A month ago, the company secured up to $250M in funding to support its CGRP receptor antagonist program through the development of zavegepant.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.